Chemed Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-58.4% vs price
Base Case (Median)
-44.1% vs price
Bull Case (75th pct.)
-15.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $121.41 | -76.9% | High (40%) |
| PE Comparable | $443.31 | -15.6% | Medium (25%) |
| Growth Trajectory DCF | $445.63 | -15.1% | Medium (20%) |
| Graham Number | $174.61 | -66.7% | Medium (40%) |
| EV/EBITDA | $293.35 | -44.1% | Medium (20%) |
| EV/FCF | $449.52 | -14.4% | Medium (20%) |
| Earnings Power Value | $261.71 | -50.1% | Medium (50%) |
Based on 7 out of 8 methods, CHE appears overvalued at the current price of $524.98. The base case fair value of $293.35 implies 44.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.